Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

Author: BaxterL M, BryantK A, EminiE A, FrenckR, GruberW C, GurtmanA, JonesT R, RubinoJ, Schmoele-ThomaB, ScottD A, SundaraiyerV, ThompsonA, TreanorJ

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the immunogenicity, tolerability, and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults. PCV13 was found to be immunogenic, safe, and well-tolerated in both PPSV23-naive adults aged 60-64 years and adults aged 18-49 years.
Paper Details　
Original Abstract of the Article :
Based on the success of vaccination with pneumococcal conjugate vaccines (PCVs) in children, recent studies have focused on PCVs in adults. Data from a randomized, double-blind study comparing the immunogenicity, tolerability, and safety of the 13-valent PCV (PCV13) and the 23-valent pneumococcal po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2015.08.080

データ提供：米国国立医学図書館（NLM）

Pneumococcal Conjugate Vaccine: A New Oasis in the Desert of Infection

This study delves into the world of pneumococcal vaccines, exploring the effectiveness and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults. The study aimed to assess the immunogenicity, tolerability, and safety of PCV13 in adults aged 18-49 years who had not previously received the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The study compared the immune response and safety profile of PCV13 in this population to that of adults aged 60-64 years, providing valuable insights into the potential benefits of PCV13 for a broader range of adults.

Pneumococcal Conjugate Vaccine: A Promising Option for Adults

This study suggests that PCV13 is safe and immunogenic in adults aged 18-49 years who have not previously received PPSV23, potentially offering a new oasis in the desert of pneumococcal infections. The research team found that PCV13 induced robust immune responses in this population, similar to those observed in older adults, highlighting its potential to protect against pneumococcal disease in a wider range of individuals. The study also emphasizes the importance of considering individual risk factors when recommending pneumococcal vaccination.

Navigating the Desert of Infectious Disease

This research offers valuable insights into the potential benefits of PCV13 for adults, highlighting its safety, immunogenicity, and potential to protect against pneumococcal disease. It emphasizes the importance of considering individual risk factors when recommending pneumococcal vaccination, particularly for individuals who may be at increased risk of infection. As we continue to explore the vast landscape of infectious diseases, this study serves as a beacon of hope, guiding us towards more effective and targeted approaches to preventing and treating infections.

Dr.Camel's Conclusion

This study highlights the safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults aged 18-49 years who have not previously received the 23-valent pneumococcal polysaccharide vaccine, potentially offering a new avenue for protecting against pneumococcal disease in a wider range of individuals.
Date :
  1. Date Completed 2016-07-27
  2. Date Revised 2018-03-04
Further Info :

Pubmed ID

26362099

DOI: Digital Object Identifier

10.1016/j.vaccine.2015.08.080

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.